OPEN ACCESS Freely available online

ISSN: 0975-0851
Journal of Bioequivalence & Bioavailability

Perspective

Improving Drug Evaluation Processes through Conventional and Innovative Bioequivalence Testing Developments

Tyson Kerlian*

Department of Pharmacy, University of Sao Paulo, Butanta, Sao Paulo, Brazil

DESCRIPTION

Bioequivalence testing is fundamental to the approval of generic drugs, ensuring they meet the same standards of efficacy and safety as brand-name products. Traditional bioequivalence studies rely heavily on pharmacokinetic assessments in clinical settings. However, recent innovations, such as pharmacokinetic modelling and real-world evidence, are revolutionizing the field.

Traditional bioequivalence testing

Traditional bioequivalence studies involve comparing the pharmacokinetic profiles of a test (generic) product and a reference product in healthy volunteers. Key parameters include:

Cmax (Maximum Concentration): The peak plasma concentration of the drug.

Tmax (Time to Maximum Concentration): The time it takes to reach Cmax.

AUC (Area Under the Curve): The total drug exposure over time.

While effective, these studies can be resource-intensive, time-consuming, and may not fully capture the variability in drug response among different populations.

Pharmacokinetic modeling and simulation

Pharmacokinetic (PK) modeling and simulation use mathematical models to predict drug behaviour in the body. These models can simulate various clinical scenarios, reducing the need for extensive invivo studies.

Reduced participant numbers: Simulations can reduce the number of participants required for bioequivalence studies.

Enhanced precision: Models can account for variability in drug absorption, distribution, metabolism, and excretion.

Ethical considerations: Minimizes the exposure of participants to potentially harmful drugs.

Case study: The use of PK modelling in the development of a generic oral contraceptive demonstrated that simulations could accurately predict bioequivalence, reducing the need for multiple clinical trials.

Real-world evidence

Real-World Evidence (RWE) involves the collection and analysis of data from real-world settings, such as Electronic Health Records (EHRs), registries, and patient-reported outcomes. RWE can complement traditional bioequivalence studies by providing insights into drug performance in diverse populations and real-life conditions.

Broader population data: Includes data from diverse patient groups, enhancing the generalizability of findings.

Long-term safety and efficacy: Provides information on the long-term safety and efficacy of drugs.

Cost-effective: Utilizes existing data sources, reducing the costs associated with clinical trials.

Case study: RWE from EHRs was used to support the bioequivalence of a generic antihypertensive drug, demonstrating its efficacy and safety in a broad patient population.

Biomarkers and surrogate endpoints

Biomarkers and surrogate endpoints are biological markers that can be used to predict therapeutic outcomes. Their use in bioequivalence studies can streamline the assessment process.

Predictive power: Biomarkers can provide early indications of therapeutic equivalence.

Reduced study duration: Surrogate endpoints can shorten the duration of bioequivalence studies.

Correspondence to: Tyson Kerlian, Department of Pharmacy, University of Sao Paulo, Butanta, Sao Paulo, Brazil, E-mail: ktyson@gmail.com

Received: 17-May-2024, Manuscript No. JBB-24-26007; **Editor assigned:** 20-May-2024, PreQC No. JBB-24-26007 (PQ); **Reviewed**: 03-Jun-2024, QC No. JBB-24-26007; **Revised:** 10-Jun-2024, Manuscript No. JBB-24-26007 (R); **Published**: 17-Jun-2024, DOI: 10.35248/0975-0851.24.16.575.

Citation: Kerlian T (2024) Improving Drug Evaluation Processes through Conventional and Innovative Bioequivalence Testing Developments. J Bioequiv Availab. 16:575.

Case study: The use of biomarkers in the bioequivalence assessment of biosimilars, such as erythropoiesis-stimulating agents, demonstrated that biomarker responses correlated well with clinical outcomes.

Regulatory perspectives

Regulatory agencies are increasingly recognizing the value of these innovations. The FDA and EMA have issued guidelines on the use of PK modelling, RWE, and biomarkers in bioequivalence assessments. Key regulatory considerations include:

Validation of models and data: Ensuring the accuracy and reliability of PK models and real-world data sources.

Ethical and legal issues: Addressing privacy concerns and informed consent when using real-world data.

Standardization: Developing standardized methodologies for the use of biomarkers and surrogate endpoints.

CONCLUSION

Innovations such as pharmacokinetic modelling, real-world evidence, and biomarkers are transforming bioequivalence testing, making it more efficient, accurate, and reflective of real-world conditions. As regulatory frameworks evolve to incorporate these advancements, the ultimate goal remains to ensure that generic drugs are as safe and effective as their brand-name counterparts, providing high-quality, and affordable medications to patients worldwide.